Your session is about to expire
← Back to Search
VP301 (Dose Escalation) for Multiple Myeloma
Study Summary
This trial will test a new drug to treat cancer that has come back or isn't responding to treatment.
- Multiple Myeloma
- Solid Tumors
- Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a heart condition that is serious.You are pregnant or breastfeeding.You are experiencing severe symptoms and complications from the spread of cancer to different parts of your body that may be life-threatening.You have already tried all the available treatments for your condition and they did not work, or those treatments are not recommended for you.You have another cancer that could make it difficult to understand the results of this study.
- Group 1: VP301 (Dose Escalation)
- Group 2: VP301 (Dose Expansion)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the VP301 (Dose Escalation) protocol been given the green light by regulatory authorities?
"Due to a lack of data on the safety and efficacy of VP301 (Dose Escalation), our team at Power has assigns it a score of one."
Can additional participants still join this trial?
"Indeed, this clinical trial is still active and accepting participants. According to the information uploaded on clinicaltrials.gov, it has been running since November 29th 2022 with updates as recent as January 16th 2023."
What is the size of the cohort participating in this clinical trial?
"Affirmative. Evidenced by information on clinicaltrials.gov, this medical study has initiated its patient recruitment phase after being posted on November 29th 2022 and updated January 16th 2023. 110 individuals will be admitted from 1 trial site."
What are the prime aims of this clinical trial?
"This clinical trial intends to evaluate the occurrence of dose-limiting toxicities, as well as monitor secondary outcomes such as changes in serum levels and objective/best responses. The study is set to run for an average of 30 months until its completion."
Share this study with friends
Copy Link
Messenger